Last ¥4,720 JPY
Change Today +18.50 / 0.39%
Volume 1.5M
4502 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:00 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
¥4,720
Previous Close
¥4,701
Day High
¥4,740
Day Low
¥4,693
52 Week High
12/10/13 - ¥5,170
52 Week Low
04/8/14 - ¥4,396
Market Cap
3.7T
Average Volume 10 Days
1.3M
EPS TTM
¥120.01
Shares Outstanding
789.7M
EX-Date
09/26/14
P/E TM
39.3x
Dividend
¥180.00
Dividend Yield
3.81%
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutical co ltd (4502) Key Developments

FDA Approves Takeda Pharmaceutical Company Limited's VELCADE(R) (bortezomib) Retreatment in Patients with Multiple Myeloma

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved VELCADE(R) (bortezomib) for the retreatment of adult patients with multiple myeloma (MM) who had previously responded to VELCADE therapy and relapsed at least six months following completion of prior VELCADE treatment. The labeling update includes dosing guidelines as well as safety and efficacy findings for the use of VELCADE as a single agent or VELCADE in combination with dexamethasone in patients previously treated with VELCADE. VELCADE retreatment may be started at the last tolerated dose. The approved retreatment sNDA consisted of a Phase 2 study and other supportive data. The Phase 2 international RETRIEVE trial showed a 38.5% overall response rate (ORR) in multiple myeloma patients who had been previously treated with a VELCADE-based regimen (median of two prior lines of therapy) and had previously achieved a partial response or better. The safety profile seen with VELCADE retreatment was consistent with the known safety profile of intravenous VELCADE in relapsed multiple myeloma; no cumulative toxicities were observed upon retreatment. The most common adverse drug reaction was thrombocytopenia, which occurred in 52% of the patients. RETRIEVE was a single arm, open-label trial. The study enrolled 130 patients ages 18 years and older who had previously responded to VELCADE-based therapy and relapsed at least six months after prior treatment with VELCADE. The study met its primary endpoint of best confirmed response to retreatment as assessed by European Group for Blood and Marrow Transplantation (EBMT) criteria. Patients had received a median of two prior therapies (range of 1-7); Dexamethasone was administered in combination with VELCADE in 94 patients. Of the 130 patients, one patient achieved complete response and 49 achieved partial response (50/130; ORR 38.5%). In the 50 responding patients, the median duration of response was 6.5 months (range of 0.6 to 19.3 months). The incidence of grade >=3 thrombocytopenia was 24%. Peripheral neuropathy occurred in 28% of patients, with the incidence of grade >=3 peripheral neuropathy reported at 6%. The incidence of serious adverse reactions was 12.3%; the most commonly reported serious adverse reactions were thrombocytopenia (3.8%), diarrhea (2.3%), herpes zoster and pneumonia (1.5% each). Adverse reactions leading to discontinuation occurred in 13% of patients.

Takeda Pharmaceutical Company Limited Reports Consolidated Earnings Results for the First Quarter of 2014; Provides Earnings Guidance for the Second Quarter, First Half and Full Year of 2014

Takeda Pharmaceutical Company Limited reported consolidated earnings results for the first quarter of 2014. For the quarter, revenue was JPY 411.1 billion against JPY 410.3 billion a year ago. Core earnings was JPY 84.3 billion against JPY 91.6 billion a year ago. Core net profit was JPY 51.9 billion or JPY 66 per share against JPY 61.8 billion or JPY 78 per share a year ago. EBITDA was JPY 113.4 billion against JPY 104.9 billion a year ago. Capital expenditure was JPY 21.2 billion against JPY 11.5 billion a year ago. Negative operating free cash flow was JPY 0.6 billion against operating free cash flow of JPY 0.1 billion a year ago. EPS was JPY 42 against JPY 46. For the second quarter of 2014, the company expects revenue of JPY 433.9 billion, operating profit of JPY 26.3 billion, net profit of JPY 16.6 billion or JPY 21 per share, core earnings of JPY 38.1 billion, core net profit of JPY 38.1 billion or JPY 48 per share. For the first half of 2014, the company expects revenue of JPY 845 billion, operating profit of JPY 90 billion, net profit of JPY 50 billion or JPY 63 per share, core earnings of JPY 145.0 billion, core net profit of JPY 90.0 billion or JPY 114 per share. For the full year of 2014, the company expects revenue of JPY 1,725 billion, operating profit of JPY 150 billion, net profit of JPY 85 billion or JPY 108 per share, core earnings of JPY 280.0 billion, core net profit of JPY 180.0 billion or JPY 228 per share.

Pfizer Japan, Inc., Takeda Pharmaceutical Company Limited and ASKA Pharmaceutical Co., Ltd Announces Reach Agreement to Conclude Their Contracts Regarding the Product SELTOUCH Activities

Pfizer Japan, Inc., Takeda Pharmaceutical Company Limited and ASKA Pharmaceutical Co. Ltd. announced that they have reached an agreement to conclude their contracts regarding the product SELTOUCH activities for both the poultice formulation and the tape formulation of Pfizer's transdermal absorption-type analgesic and anti-inflammatory agent SELTOUCH (SELTOUCH PAP 70, SELTOUCH PAP 140, and SELTOUCH TAPE 70) by Takeda and ASKA will be concluded. Effective from October 1, 2014, Pfizer will conduct the distribution and marketing activities for this product. The three companies will work closely to smoothly implement the marketing transfer of SELTOUCH. The companies remain committed to contributing to healthcare by providing therapeutical treatment options that address unmet needs of patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥4,719.50 JPY +18.50

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.80 USD +0.31
Astellas Pharma Inc ¥1,523 JPY +3.00
Baxter International Inc $75.53 USD +0.13
Becton Dickinson and Co $117.73 USD +0.27
Eli Lilly & Co $62.81 USD +0.08
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 34.7x
Price/Sales 2.1x
Price/Book 1.5x
Price/Cash Flow 16.0x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.